Search for: "Mylan Pharmaceuticals"
Results 461 - 480
of 739
Sort by Relevance
|
Sort by Date
24 Jun 2011, 3:25 pm
”Certiorari stage documents:Opinion below (3d Circuit)Petition for certiorariBrief in oppositionPetitioners' supplemental briefRespondents' supplemental briefPetitioners' replyAmicus brief of TEVA Pharmaceuticals USA, Inc.Amicus brief of Consumer Federation of America et al.Amicus brief of Mylan Pharmaceuticals, Inc.Amicus brief of Apotex, Inc.Amicus Generic Pharmaceutical AssociationCVSG Information:Invited: March 28, 2011Filed: May 26, 2011… [read post]
24 Jun 2011, 12:44 pm
They eventually concluded that this was down to the size of the particles making up the input active pharmaceutical ingredient (the “API”) used in the US trials. [read post]
23 Jun 2011, 11:16 pm
Reddys Laboratories Mylan Pharmaceuticals Teva Aurobindo Pharma Glenmark Generics Lupin Wockhardt These companies and others are now allowed to sell their versions of Levaquin in the United States, which so far has earned $ 1.45 billion for a period of 12 months ending in September, 2010. [read post]
17 Jun 2011, 2:25 am
The Bedford Report keeps an eye on healthcare companies and provides research reports on Teva Pharmaceutical Industries Limited (makers of generic Yasmin) and Mylan Inc., the makers of Effexor. [read post]
15 Jun 2011, 4:56 am
Mylan Inc. et al. [read post]
14 Jun 2011, 9:24 pm
• Defendants: Mylan Inc.; Mylan Pharmaceuticals, Inc. [read post]
31 May 2011, 8:38 pm
General WIPO SCP16: Joint proposal of the African Group and the Development Agenda Group on a work program on Patents and Health (Knowledge Ecology International) Rogue pharmacies slide under Google radar (IP Osgoode) Australia slips further out-of-step on pharmaceutical extensions (Patentology) EU: Proposed EU Customs Regulation may not dispel fear of wrongful drug seizures (IP Watch) EU: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other… [read post]
Obama Administration Urges Supreme Court to Grant Certiorari in Case on Orange Book Patent Use Codes
30 May 2011, 9:49 pm
PIRG; the Generic Pharmaceutical Association (GPhA); Mylan; and Teva. [read post]
27 May 2011, 8:56 am
”Certiorari stage documents:Opinion below (3d Circuit)Petition for certiorariBrief in oppositionPetitioners' replyAmicus brief of TEVA Pharmaceuticals USA, Inc.Amicus brief of Consumer Federation of America et al.Amicus brief of Mylan Pharmaceuticals, Inc.Amicus brief of Apotex, Inc.Amicus Generic Pharmaceutical AssociationCVSG Information:Invited: March 28, 2011Filed: May 26, 2011 (Grant) Title: National Meat Association v. [read post]
26 May 2011, 10:54 am
Mylan, Inc., 718 F. [read post]
25 May 2011, 4:59 am
Highlights this week included: District Court Delaware grants TRO against Mylan’s generic Amrix, after finding patents invalid: In Re Cyclobenzaprine Hyldrochloride Extended-Release Capsule Patent Litigation (Orange Book Blog) (Patent Docs) Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
18 May 2011, 12:33 am
Sun Pharmaceuticals on question of obviousness-type double patenting (Patent Docs) (IPBiz) Glumetza (Metformin) – US: Depomed receives notice of Para IV certification against patents from second ANDA filer, Sun Pharmaceutical (GenericsWeb) Myfortic7 (Mycophenolate) – US: Novartis files patent infringement complaint against Teva in response to Para IV certification filing (Patent Docs) NuvaRing (Etonogestrel, Estradiol) – US: ALJ Luckern sets procedural schedule in… [read post]
15 May 2011, 9:07 pm
UPDATE: On May 16, Watson Pharmaceuticals announced that it launched an authorized generic version of Amrix, supplied by Cephalon's Anesta AG subsidiary. [read post]
11 May 2011, 4:54 am
ARUP: Genetic testing patents found to be anticipated and in violation of Lilly written description requirement (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O) US: FDA gets the ball rolling on biosimilar/interchangeable biological product user fee program; proposal gives a hat tip to PDUFA while acknowledging the nascent state of the industry (FDA Law Blog) (Patent Docs) Products Citalopram – UK Patents Court disapproving of EPO’s approach to assessment of novelty: Lundbeck v… [read post]
5 May 2011, 11:29 am
One company, Mylan, has even sued the FDA, alleging that the government's indecision has crimped the ability of competitors to plan. [read post]
4 May 2011, 7:52 am
Generic Opioid Products Generic Name Drug Name Applicant/Sponsors Fentanyl Fentanyl Extended Release Transdermal System Actavis Fentanyl Fentanyl Extended Release Transdermal System Lavipharm Labs Fentanyl Fentanyl Extended Release Transdermal System Mylan Technologies Fentanyl Fentanyl Extended Release Transdermal System Teva Pharms Fentanyl Fentanyl Extended Release Transdermal System Watson … [read post]
4 May 2011, 4:13 am
Purepac Pharmaceutical, et. al. [read post]
3 May 2011, 7:16 am
Mylan Pharmaceuticals Inc. has lost its bid in Washington federal court to force a U.S. [read post]
28 Apr 2011, 3:18 pm
By now Restatement (Second) of Torts §402A (1965) is so old as to be thought of as somewhat antediluvian. [read post]
27 Apr 2011, 6:44 am
Mylan Pharmaceuticals, Inc., C.A. [read post]
